PL1701941T3 - Związki przeznaczone do leczenia chorób, związanych z proliferacją komórek - Google Patents
Związki przeznaczone do leczenia chorób, związanych z proliferacją komórekInfo
- Publication number
- PL1701941T3 PL1701941T3 PL04813958T PL04813958T PL1701941T3 PL 1701941 T3 PL1701941 T3 PL 1701941T3 PL 04813958 T PL04813958 T PL 04813958T PL 04813958 T PL04813958 T PL 04813958T PL 1701941 T3 PL1701941 T3 PL 1701941T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- treatment
- cell proliferative
- proliferative diseases
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52887703P | 2003-12-11 | 2003-12-11 | |
| PCT/US2004/041712 WO2005058829A1 (en) | 2003-12-11 | 2004-12-13 | Compounds for treatment of cell proliferative diseases |
| EP04813958A EP1701941B1 (en) | 2003-12-11 | 2004-12-13 | Compounds for treatment of cell proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1701941T3 true PL1701941T3 (pl) | 2012-11-30 |
Family
ID=34699909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04813958T PL1701941T3 (pl) | 2003-12-11 | 2004-12-13 | Związki przeznaczone do leczenia chorób, związanych z proliferacją komórek |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7745468B2 (pl) |
| EP (2) | EP2487156B1 (pl) |
| JP (1) | JP4751336B2 (pl) |
| KR (2) | KR101170655B1 (pl) |
| CN (2) | CN1894215B (pl) |
| AU (1) | AU2004298511B2 (pl) |
| BR (1) | BRPI0416981A (pl) |
| CA (1) | CA2548152C (pl) |
| DK (1) | DK1701941T3 (pl) |
| ES (1) | ES2385831T3 (pl) |
| IL (1) | IL176028A (pl) |
| MX (1) | MXPA06006460A (pl) |
| PL (1) | PL1701941T3 (pl) |
| PT (1) | PT1701941E (pl) |
| SI (1) | SI1701941T1 (pl) |
| WO (1) | WO2005058829A1 (pl) |
| ZA (1) | ZA200604682B (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1701941T3 (da) | 2003-12-11 | 2012-08-13 | Univ Texas | Forbindelser til behandling af sygdomme med celleproliferation |
| BRPI0617364A2 (pt) * | 2005-10-13 | 2011-07-26 | Orchid Res Lab Ltd | compostos heterocÍclicos como inibidores de pstat3/il-6 |
| US8779151B2 (en) * | 2006-03-31 | 2014-07-15 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
| WO2008005954A2 (en) * | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| EP2446903B1 (en) | 2006-11-20 | 2019-10-09 | President and Fellows of Harvard College | Compositions for treating itch |
| US20080167277A1 (en) * | 2006-12-29 | 2008-07-10 | Charles Conrad | Methods of treating skin disorders with caffeic acid analogs |
| US20100144802A1 (en) * | 2007-03-28 | 2010-06-10 | Heimberger Amy B | Small Molecule Inhibitors for Immune Modulation |
| EP3067054B1 (en) * | 2007-09-10 | 2020-12-30 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| UA103492C2 (ru) * | 2008-07-08 | 2013-10-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) |
| US8450337B2 (en) * | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
| CA2738786C (en) | 2008-09-30 | 2017-12-19 | Mallinckrodt Inc. | A version of fdg detectable by single-photon emission computed tomography |
| US20120021941A1 (en) * | 2009-01-12 | 2012-01-26 | The Board Of Regents Of The University Of Texas System | Blood test for the detection of cancer |
| US20120172429A1 (en) | 2009-07-10 | 2012-07-05 | Woolf Clifford J | Permanently charged sodium and calcium channel blockers as anti- inflammatory agents |
| JP5940452B2 (ja) | 2009-10-16 | 2016-06-29 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 殺菌剤としてのアミノプロペン酸化合物 |
| EP2506852A4 (en) | 2009-12-04 | 2013-06-19 | Univ Texas | INTERFERONTHERAPIES IN COMBINATION WITH BLOCKING OF STAT3 ACTIVATION |
| EP2544686A4 (en) * | 2010-02-05 | 2013-06-26 | Whitehead Biomedical Inst | COMBINATION PROCEDURE FOR THE TREATMENT OF A DISEASE |
| AU2011227023B2 (en) | 2010-03-19 | 2015-05-28 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
| WO2012040527A2 (en) * | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| EP2510787A1 (en) | 2011-04-15 | 2012-10-17 | Bayer Cropscience AG | Propenoates as fungicides |
| JPWO2012165262A1 (ja) | 2011-05-27 | 2015-02-23 | 国立大学法人徳島大学 | ベンジルアミン誘導体 |
| WO2013009872A1 (en) | 2011-07-11 | 2013-01-17 | The Regents Of The University Of Michigan | Multimodality left atrial appendage occlusion device |
| BR112014029439A2 (pt) * | 2012-05-25 | 2017-06-27 | Governing Council Univ Toronto | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos |
| JP6486272B2 (ja) | 2012-09-07 | 2019-03-20 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 有毛細胞および／または支持細胞再生のための方法および組成物 |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| MX2015014181A (es) | 2013-04-09 | 2016-05-24 | Boston Biomedical Inc | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. |
| WO2015002766A1 (en) * | 2013-07-02 | 2015-01-08 | Nikolai Khodarev | Anti-tumor therapy |
| US9868736B2 (en) | 2013-10-10 | 2018-01-16 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| EP3212773B1 (en) | 2014-10-29 | 2021-09-15 | Massachusetts Eye and Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
| US11021443B2 (en) | 2015-08-03 | 2021-06-01 | President And Fellows Of Harvard College | Charged ion channel blockers and methods for use |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
| TWI846678B (zh) | 2017-11-10 | 2024-07-01 | 美國德州系統大學評議委員會 | 咖啡酸衍生物及其用途 |
| US11590152B2 (en) | 2018-01-26 | 2023-02-28 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP7692834B2 (ja) | 2019-03-11 | 2025-06-16 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| CA3129111A1 (en) | 2019-03-11 | 2020-09-17 | Bridget M. Cole | Charged ion channel blockers and methods for use |
| MA55320A (fr) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation |
| JP2022520287A (ja) * | 2019-04-02 | 2022-03-29 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の治療のための転写インヒビターと免疫チェックポイントインヒビターの組み合わせ |
| JP2022527114A (ja) | 2019-04-05 | 2022-05-30 | カイメラ セラピューティクス， インコーポレイテッド | 分解剤およびそれらの使用 |
| CN114828845A (zh) | 2019-11-06 | 2022-07-29 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| EP4118070A4 (en) | 2020-03-11 | 2024-04-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN115381822A (zh) * | 2022-05-11 | 2022-11-25 | 暨南大学附属第一医院（广州华侨医院） | 一种基于激活免疫应答治疗肺癌的药物及制药应用 |
| KR102811597B1 (ko) * | 2022-06-22 | 2025-05-22 | 한국생명공학연구원 | 신규한 신남아마이드 유도체 및 이의 용도 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2555789A1 (de) | 1975-12-11 | 1977-07-07 | Hoechst Ag | Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
| FR2629455B1 (fr) * | 1988-03-29 | 1991-09-27 | Rhone Poulenc Agrochimie | Derives de 2-(3-pyridinyl)3-(phenoxy) propanenitrile |
| GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
| EP0527181A4 (en) | 1990-04-16 | 1993-04-07 | Rorer International (Holdings) | Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase |
| US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| CA2080554A1 (en) * | 1991-10-15 | 1993-04-16 | Mitsubishi Chemical Corporation | Styrene derivatives |
| JPH05301838A (ja) * | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| CA2092017A1 (en) | 1992-03-26 | 1993-09-27 | Tameo Iwasaki | Butadiene derivatives and process for preparing the same |
| US5981569A (en) | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
| JPH06247850A (ja) | 1993-02-24 | 1994-09-06 | Suntory Ltd | １２−リポキシゲナーゼ阻害剤 |
| DE69414394T2 (de) | 1993-07-27 | 1999-05-12 | The University Of Birmingham, Edgbaston, Birmingham | Strassendecken |
| GB9322781D0 (en) * | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
| IL107736A (en) | 1993-11-24 | 2001-01-11 | Yissum Res Dev Co | Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases |
| IL112205A0 (en) | 1994-01-06 | 1995-03-15 | Res Dev Foundation | Curcumin, analogues of curcumin and novel uses thereof |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9406137D0 (en) * | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
| EP0754038A1 (en) | 1994-04-22 | 1997-01-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of benzylidene-malononitrile derivates for the treatment of leukemia |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| US5854285A (en) | 1997-04-03 | 1998-12-29 | Natpro, Inc. | Protein kinase inhibitor |
| US6420338B1 (en) | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| EP1000935A4 (en) * | 1997-07-25 | 2001-03-21 | Tsumura & Co | PYRIDYL ACRYLAMIDE DERIVATIVES AND DRUGS AGAINST NEPHRITIS AND INHIBITORS OF THE TRANSFORMING GROWTH FACTOR BETA CONTAINING THESE DERIVATIVES |
| US6225346B1 (en) | 1997-10-24 | 2001-05-01 | Sugen, Inc. | Tyrphostin like compounds |
| KR100674760B1 (ko) | 1999-03-04 | 2007-01-25 | 리가가쿠 겐큐쇼 | 촉매 조성물 |
| US20020045191A1 (en) | 2000-09-15 | 2002-04-18 | Schneider Robert J. | Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| JP2003119169A (ja) | 2001-07-30 | 2003-04-23 | Shigetoshi Kadota | 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物 |
| US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| AU2002349621A1 (en) | 2001-11-30 | 2003-06-10 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| AU2003294441A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| KR20050055479A (ko) | 2003-12-08 | 2005-06-13 | 김철호 | 카페인산 또는 카페인산 페네틸에스테르를 유효성분으로하는 ｍｍｐ-9 억제제 |
| DK1701941T3 (da) | 2003-12-11 | 2012-08-13 | Univ Texas | Forbindelser til behandling af sygdomme med celleproliferation |
| US8779151B2 (en) * | 2006-03-31 | 2014-07-15 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
| WO2008005954A2 (en) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| EP2104424A4 (en) * | 2006-10-30 | 2011-06-15 | Wockhardt Research Center | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA |
-
2004
- 2004-12-13 DK DK04813958.8T patent/DK1701941T3/da active
- 2004-12-13 PT PT04813958T patent/PT1701941E/pt unknown
- 2004-12-13 JP JP2006544085A patent/JP4751336B2/ja not_active Expired - Fee Related
- 2004-12-13 AU AU2004298511A patent/AU2004298511B2/en not_active Ceased
- 2004-12-13 KR KR1020067013861A patent/KR101170655B1/ko not_active Expired - Fee Related
- 2004-12-13 WO PCT/US2004/041712 patent/WO2005058829A1/en not_active Ceased
- 2004-12-13 MX MXPA06006460A patent/MXPA06006460A/es active IP Right Grant
- 2004-12-13 PL PL04813958T patent/PL1701941T3/pl unknown
- 2004-12-13 CN CN2004800370450A patent/CN1894215B/zh not_active Expired - Fee Related
- 2004-12-13 US US11/010,834 patent/US7745468B2/en active Active
- 2004-12-13 BR BRPI0416981-6A patent/BRPI0416981A/pt not_active IP Right Cessation
- 2004-12-13 SI SI200431908T patent/SI1701941T1/sl unknown
- 2004-12-13 CN CN2012100233394A patent/CN102603565A/zh active Pending
- 2004-12-13 CA CA2548152A patent/CA2548152C/en not_active Expired - Lifetime
- 2004-12-13 KR KR1020117027869A patent/KR101218633B1/ko not_active Expired - Fee Related
- 2004-12-13 ES ES04813958T patent/ES2385831T3/es not_active Expired - Lifetime
- 2004-12-13 EP EP12167605.0A patent/EP2487156B1/en not_active Expired - Lifetime
- 2004-12-13 EP EP04813958A patent/EP1701941B1/en not_active Expired - Lifetime
-
2006
- 2006-05-30 IL IL176028A patent/IL176028A/en active IP Right Review Request
- 2006-06-07 ZA ZA2006/04682A patent/ZA200604682B/en unknown
-
2010
- 2010-06-28 US US12/824,901 patent/US8119827B2/en not_active Expired - Fee Related
-
2012
- 2012-01-13 US US13/350,637 patent/US8648102B2/en not_active Expired - Fee Related
-
2014
- 2014-01-03 US US14/147,089 patent/US9096499B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL176028A0 (en) | Compounds for treatment of cell proliferative diseases | |
| IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
| ZA200508427B (en) | Methods for treating interleuking-6 related diseases | |
| IL172346A0 (en) | Treatment of t cell mediated diseases by inhibition of fgfr3 | |
| IL178860A (en) | Certain chemical entities, preparations and processes | |
| IL180729A0 (en) | Compounds and methods for treatment of cancer | |
| IL181305A0 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| PL375532A1 (pl) | Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów | |
| PL2001892T3 (pl) | Imidazolotiazolowe związki do leczenia chorób proliferacyjnych | |
| IL173386A0 (en) | Use of adcc-optimized antibodies for treating weak patients | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| PL1685125T3 (pl) | Pochodne pirrolowe użyteczne do leczenia chorób proliferacyjnych | |
| GB0305150D0 (en) | Use of therapeutic compounds | |
| IL175535A0 (en) | Compositions for treatment of neurodegenerative diseases | |
| EP1709155A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DYSPROLIFERATIVE DISEASES AND METHODS OF THEIR USE | |
| PL1801108T3 (pl) | Związki morfolinowe do leczenia stanów zapalnych | |
| GB0400802D0 (en) | Compounds for the treatment of disease | |
| PT1742937E (pt) | Derivados de pirrolopirimidina úteis para o tratamento de doenças proliferativas | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| SI1535612T1 (sl) | Zdravljenje hiperurikemije | |
| IL175611A0 (en) | Combinations for the treatment of proliferative diseases | |
| AP2006003728A0 (en) | Compounds for treatment of diseases | |
| GB0425073D0 (en) | Compounds for the treatment of diseases | |
| GB0420867D0 (en) | Compounds for the treatment of diseases | |
| GB0425064D0 (en) | Compounds useful for the treatment of diseases |